

Munich Cancer Registry



- ▶ Incidence and Mortality
- ▶ Selection Matrix
- ▶ Homepage
- ▶ *Deutsch*

ICD-10 C00-C96.9: All cancers (excl. C44)

Survival

Year of diagnosis	1988-1997	1998-2019
Patients	62,878	409,162
Diseases	66,364	455,600
Cases evaluated	58,568	334,770
Creation date	01/27/2021	
Database export	01/07/2021	
Population	4.92 m	



Munich Cancer Registry
Cancer Registry Bavaria - Upper Bavaria Regional Center
at Klinikum Grosshadern/IBE
Marchioninstr. 15
Munich, 81377
Germany

<https://www.tumorregister-muenchen.de/en>

<https://www.tumorregister-muenchen.de/en/facts/surv/sC0096E-ICD-10-C00-C96.9-All-cancers-excl.-C44-survival.pdf>

Index of figures and tables

Fig./Tbl.		Page
1a	Relative survival by year of diagnosis (chart)	3
1b	Survival by year of diagnosis (table)	3
2a	Survival by sex (chart)	5
2b	Survival by sex (table)	5
2c	Conditional survival by sex (chart)	6
2d	Conditional survival by sex (table)	6
3a	Observed survival by age category (chart)	7
3b	Relative survival by age category (chart)	7
3c	Survival by age category (table)	8
4a	Relative survival by morphology (chart)	9
4b	Survival by morphology (table)	9
5a	Time to first progression (chart)	11
5b	Time to first progression (table)	11
5c	Observed post-progression survival (chart)	13
5d	Observed post-progression survival (table)	13
5e	Observed post-progression survival by period of progression (chart)	14
5f	Observed post-progression survival by period of progression (table)	14




Figure 1a. Relative survival of patients with all cancers (excl. C44) by year of diagnosis. Included in the evaluation are 326,843 cases diagnosed between 1998 and 2019.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 2000 to 2017, and are represented by colored diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided population-based statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

Years	Year of diagnosis													
	1998 n=9,472		1999 n=9,401		2000 n=9,169		2001 n=9,482		2002 n=15,629		2003 n=15,728		2004 n=16,037	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	77.6	80.0	78.7	81.1	80.8	83.1	80.8	83.0	81.0	83.3	80.5	82.7	80.9	83.1
2	68.8	72.8	69.9	73.8	72.2	76.2	71.8	75.6	71.9	75.8	71.8	75.7	72.2	75.9
3	63.3	68.7	64.2	69.5	66.4	71.8	66.4	71.6	66.5	71.9	66.5	71.8	66.7	71.7
4	59.5	66.1	60.1	66.6	62.4	69.1	62.4	68.8	62.6	69.3	62.6	69.2	62.8	69.2
5	56.1	63.9	56.7	64.4	58.6	66.4	58.8	66.4	59.4	67.4	59.4	67.2	59.7	67.3
6	53.3	62.2	53.8	62.6	55.9	64.8	56.1	64.7	56.2	65.4	56.6	65.7	56.9	65.7
7	50.5	60.3	51.2	61.0	53.3	63.4	53.6	63.3	53.4	63.7	53.8	64.0	54.1	64.0
8	48.0	58.9	49.0	59.7	51.0	62.1	51.3	62.1	51.1	62.5	51.5	62.8	51.7	62.7
9	45.7	57.4	46.8	58.4	48.9	61.0	49.2	60.9	48.7	61.1	49.2	61.7	49.5	61.5
10	43.3	55.8	44.7	57.2	46.7	59.8	47.2	60.0	46.6	60.0	46.8	60.3	47.4	60.5
11	41.2	54.5	42.8	56.1	44.8	58.7	45.2	58.9	44.6	59.0	44.8	59.1	45.3	59.3
12	39.7	53.8	41.0	55.1	42.8	57.7	43.4	58.0	42.7	58.1	42.6	57.9	43.4	58.4
13	37.9	52.6	39.1	53.9	41.0	56.7	41.2	56.6	40.8	57.1	40.8	57.0	41.4	57.2
14	36.1	51.6	37.5	53.2	39.1	55.5	39.3	55.4	38.9	56.1	38.6	55.6	39.3	55.8
15	34.3	50.4	36.1	52.4	37.4	54.6	37.8	54.7	36.8	54.6	36.9	54.7	37.8	55.3
Median	7.1		7.5		8.4		8.6		8.4		8.6		8.7	

cont'd	Year of diagnosis													
	2006		2007		2008		2009		2010		2011		2013	
	n=16,154		n=18,729		n=18,888		n=18,556		n=18,199		n=18,211		n=17,944	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	80.1	82.2	79.7	81.7	81.0	83.1	80.8	82.9	80.6	82.7	80.4	82.5	81.0	83.1
2	71.2	74.9	71.1	74.7	72.6	76.2	72.1	75.6	72.3	75.8	71.8	75.4	72.2	75.7
3	65.8	70.8	65.3	70.2	67.2	72.2	66.9	71.7	67.1	71.9	66.6	71.5	66.8	71.6
4	61.9	68.3	60.9	67.0	63.5	69.7	62.9	69.0	63.4	69.5	62.9	69.0	62.7	68.7
5	58.8	66.5	57.5	64.8	60.3	67.8	59.9	67.3	60.2	67.5	59.8	67.2	59.5	66.6
6	55.9	64.7	54.4	62.8	57.8	66.4	57.1	65.6	57.5	65.9	57.1	65.6	57.4	65.7
7	53.1	63.1	51.6	61.0	55.1	65.0	54.4	64.0	54.8	64.4	54.6	64.3		
8	50.6	61.6	48.9	59.4	53.0	64.0	52.0	62.7	52.5	63.1	52.9	63.7		
9	48.3	60.3	46.7	58.2	50.8	62.9	50.3	62.0	50.6	62.3				
10	46.1	59.1	44.4	56.7	48.9	62.1	48.3	61.1						
11	43.8	57.8	42.4	55.6	47.1	61.5								
12	41.6	56.4	40.6	54.6										
13	40.0	55.8												
Median	8.3		7.6		9.4		9.1							

cont'd	Year of diagnosis											
	2014		2015		2016		2017		2018		2019	
	n=17,395		n=16,529		n=15,337		n=14,243		n=12,491		n=4,952	
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	79.7	81.8	78.8	80.8	78.1	80.1	81.9	83.9	87.1	89.1		
2	71.3	74.7	68.9	72.3	70.4	73.7	75.7	79.3				
3	65.8	70.6	63.4	68.0	66.4	71.1						
4	62.0	68.0	60.1	65.8								
5	59.5	66.8										
Median												

Table 1b. Observed (obs.) and relative (rel.) survival of patients with all cancers (excl. C44) by year of diagnosis for period 1998-2019 (N=326,843).




Figure 2a. Survival of patients with all cancers (excl. C44) by sex. Included in the evaluation are 326,843 cases diagnosed between 1998 and 2019. Subgroups with sample size <20 are omitted from the chart.

Years	Sex			
	Male n=165,063		Female n=161,777	
	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	78.4	80.8	82.7	84.6
2	69.2	73.2	74.9	78.0
3	63.6	69.3	69.7	73.9
4	59.6	66.8	65.8	71.1
5	56.2	64.9	62.8	69.0
6	53.3	63.5	60.1	67.2
7	50.6	62.1	57.6	65.6
8	48.1	60.9	55.4	64.3
9	45.8	59.9	53.4	63.1
10	43.6	58.9	51.3	61.8
11	41.4	57.9	49.4	60.7
12	39.3	56.9	47.6	59.7
13	37.2	55.9	45.7	58.6
14	35.2	54.9	43.9	57.4
15	33.4	54.2	42.2	56.3
Median	7.3		10.7	

Table 2b. Observed (obs.) and relative (rel.) survival of patients with all cancers (excl. C44) by sex for period 1998-2019 (N=326,843).




Figure 2c. Conditional relative 2 / 5-year survival of patients with all cancers (excl. C44) by sex. For 326,843 of 326,843 cases diagnosed between 1998 and 2019 valid data could be obtained for this item. Subgroups with sample size <20 are omitted from the chart.

Years	Sex								
	Male			Female			Diverse		
	n	Cond. surv. %		n	Cond. surv. %		n	Cond. surv. %	
	n	2 yrs	5 yrs	n	2 yrs	5 yrs	n	2 yrs	5 yrs
0	165,063	73.2	64.9	161,777	78.0	69.0	3		
1	122,296	85.9	78.9	125,217	87.5	79.8			
2	102,732	91.5	85.5	106,819	91.5	84.7			
3	89,478	94.3	88.9	93,126	93.8	88.0			
4	79,137	95.7	91.1	82,306	95.2	90.0			
5	69,962	96.5	92.5	72,959	95.8	91.1			
6	61,339	97.0	93.4	64,326	96.6	92.0			
7	53,263	97.6	94.2	56,201	97.3	93.0			
8	45,880	98.1	94.8	48,955	97.3	93.3			
9	39,268	98.3	95.1	42,003	97.5	93.4			
10	33,360	98.4	95.9	35,589	97.9	93.7			

Table 2d. Conditional relative 2 / 5-year survival of patients with all cancers (excl. C44) by sex for period 1998-2019 (N=326,843).

Conditional relative survival rates refer to the relative survival probability, in this case for 2 and 5 years after cancer diagnosis, compared to the age- and sex-matched population (=100 %) under the condition of being alive for a certain time period (x-axis in Figure 2a). The results illustrate to what extent the cancer induced mortality of particular subgroups declines in the subsequent years after detection of the malignancy. For instance, according to the presented survival statistics, patients in the subgroup sex="Male", who are alive at least 3 years after cancer diagnosis, the conditional relative 2-year survival rate is 94.3% (n=89,478).




Figure 3a. Observed survival of patients with all cancers (excl. C44) by age category. Included in the evaluation are 326,843 cases diagnosed between 1998 and 2019.




Figure 3b. Relative survival of patients with all cancers (excl. C44) by age category. Included in the evaluation are 326,843 cases diagnosed between 1998 and 2019.

Years	Age category													
	0-29 yrs n=6,522		30-39 yrs n=12,222		40-49 yrs n=29,197		50-59 yrs n=57,777		60-69 yrs n=91,644		70-79 yrs n=87,004		80-89 yrs n=37,833	
	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	96.0	96.0	95.7	95.7	91.4	91.5	86.3	86.8	83.2	84.3	76.5	78.9	63.0	68.8
2	92.4	92.4	91.9	92.0	85.5	85.8	78.3	79.2	75.2	77.2	67.0	71.5	50.8	60.9
3	90.3	90.4	89.2	89.4	81.7	82.2	73.9	75.1	70.2	73.2	60.9	67.4	42.4	56.5
4	89.0	89.1	87.5	87.8	79.3	79.9	70.7	72.4	66.7	70.6	56.2	64.8	36.1	53.9
5	88.1	88.3	86.1	86.5	77.5	78.3	68.4	70.5	63.9	68.8	52.2	62.9	30.7	51.9
6	87.5	87.7	84.8	85.2	75.7	76.8	66.4	69.0	61.4	67.4	48.6	61.5	26.0	50.3
7	86.5	86.7	83.5	84.0	74.3	75.5	64.6	67.7	59.1	66.2	45.1	60.2	21.8	48.9
8	85.8	86.1	82.5	83.1	73.2	74.6	63.1	66.7	57.1	65.4	41.7	59.0	18.2	48.1
9	85.3	85.6	81.7	82.4	72.0	73.8	61.5	65.7	55.2	64.7	38.4	58.1	14.9	47.3
10	85.0	85.3	80.9	81.8	71.1	73.1	60.1	64.8	53.1	63.9	35.2	57.2	12.0	46.3
Median							17.5		11.6		5.6		2.1	

Years	Age category <i>cont'd</i> 90+ yrs n=4,644	
	obs. %	rel. %
0	100.0	100.0
1	47.6	59.9
2	32.9	53.0
3	23.0	48.3
4	17.0	47.5
5	12.2	46.5
6	8.8	46.3
7	6.1	46.1
8	4.3	46.1
9	3.0	48.8
10	2.2	54.8
Median	0.9	

Table 3c. Observed (obs.) and relative (rel.) survival of patients with all cancers (excl. C44) by age category for period 1998-2019 (N=326,843).




Figure 4a. Relative survival of patients with all cancers (excl. C44) by morphology. For 321,537 of 326,843 cases diagnosed between 1998 and 2019 valid data could be obtained for this item.

Years	Morphology													
	Epithelial npl., NOS		Squamous cell npl.		Adenocarcinomas		Cystic, mucin.a. serous npl.		Ductal and lobular neoplasms		Melanomas		Hodgkin a. non-Hodgkin l.	
	n=12,794	n=25,546	n=144,887	n=12,600	n=55,158	n=16,107	n=11,117							
0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1	44.0	45.2	70.7	72.3	81.2	83.7	73.9	76.1	93.6	95.1	95.7	97.6	82.4	84.4
2	28.5	30.0	57.1	59.5	73.4	77.7	60.5	63.8	88.4	91.3	91.6	95.1	76.4	79.7
3	23.6	25.5	50.0	53.2	68.0	74.1	51.8	56.0	84.1	88.2	88.1	93.2	72.8	77.4
4	20.8	23.1	45.7	49.6	64.0	71.9	45.7	50.8	80.5	85.8	85.5	92.0	69.3	75.2
5	18.9	21.5	42.6	47.0	60.7	70.2	41.6	47.4	77.4	83.7	83.1	91.0	66.4	73.4
6	17.6	20.5	39.9	44.9	57.7	68.8	38.2	44.8	74.5	82.0	80.8	90.1	63.5	71.5
7	16.3	19.5	37.3	42.8	55.0	67.6	35.3	42.6	71.8	80.2	78.4	89.0	60.9	69.7
8	15.2	18.7	35.1	41.1	52.4	66.5	33.2	41.2	69.3	78.6	76.7	88.6	58.5	68.3
9	14.1	17.8	33.1	39.4	50.0	65.7	31.4	40.1	66.9	77.3	74.7	87.9	56.4	66.9
10	13.2	17.1	31.4	38.2	47.6	64.8	29.6	38.9	64.4	75.7	72.7	87.1	54.2	65.5
Median	0.8		3.0		9.0		3.3		17.2				12.0	

Morphology				
<i>cont'd</i>	Mult. morphology n=8,611		NOS n=34,717	
Years	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0
1	80.6	82.5	76.4	78.4
2	70.8	74.0	65.3	68.4
3	64.6	68.9	59.2	63.2
4	60.9	66.2	54.9	59.7
5	57.5	63.8	51.6	57.2
6	54.9	62.2	48.8	55.1
7	52.6	60.7	46.4	53.3
8	50.7	59.8	44.4	51.9
9	48.9	58.9	42.5	50.5
10	47.0	57.8	40.7	49.3
Median	8.4		5.6	

Table 4b. Observed (obs.) and relative (rel.) survival of patients with all cancers (excl. C44) by morphology for period 1998-2019 (N=321,537).




Figure 5a. Time to first progression of 325,026 patients with all cancers (excl. C44) diagnosed between 1998 and 2019 (in solid cancers M0 only) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

		Type of progression						Distant metastasis (CI)
		Any type (CI)	Any type (1-KM)	Local relapse (CI)	Local relapse (1-KM)	Lymph node (CI)	Lymph node (1-KM)	
N		275,152	275,152	325,021	325,021	325,025	325,025	275,196
Events		94,084	94,084	22,586	22,586	7,500	7,500	43,676
compet.		40,034		139,580		149,899		74,534
Years	%	%	%	%	%	%	%	%
0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
1	17.5	17.8	2.2	2.5	0.7	0.8	5.7	
2	24.7	25.3	4.1	5.0	1.3	1.6	9.8	
3	28.5	29.4	5.2	6.5	1.7	2.2	12.1	
4	31.0	32.0	5.9	7.5	1.9	2.5	13.7	
5	32.8	34.0	6.4	8.3	2.1	2.8	14.8	
6	34.1	35.6	6.8	9.0	2.2	3.0	15.7	
7	35.2	36.9	7.1	9.6	2.4	3.2	16.4	
8	36.1	37.9	7.4	10.1	2.5	3.4	16.9	
9	36.9	38.9	7.6	10.6	2.6	3.6	17.4	
10	37.6	39.8	7.9	11.0	2.6	3.7	17.9	
11	38.2	40.5	8.1	11.4	2.7	3.9	18.2	
12	38.7	41.2	8.2	11.8	2.7	4.0	18.6	
13	39.1	41.9	8.4	12.2	2.8	4.1	18.9	
14	39.5	42.5	8.6	12.5	2.8	4.3	19.1	
15	39.9	43.0	8.7	12.9	2.9	4.3	19.3	

<i>cont'd</i>	Type of progression		
	Distant metast. (1- KM)	NOS (CI)	NOS (1-KM)
N	275,196	324,987	324,987
Events	43,676	44,328	44,328
compet.		120,569	
Years	%	%	%
0	0.0	0.0	0.0
1	6.1	8.9	9.6
2	10.6	11.2	12.4
3	13.4	12.3	13.8
4	15.3	12.9	14.8
5	16.8	13.4	15.5
6	17.9	13.8	16.1
7	18.8	14.1	16.6
8	19.6	14.4	17.0
9	20.3	14.6	17.3
10	20.9	14.7	17.6
11	21.5	14.9	17.9
12	22.0	15.0	18.2
13	22.5	15.1	18.4
14	23.0	15.2	18.6
15	23.3	15.3	18.8

Table 5b. Time to first progression of patients with all cancers (excl. C44) for period 1998-2019 (N=325,026), also showing the total of progression events (Events) and of deaths as competing risk (compet.).




Figure 5c. Observed post-progression survival of 112,002 patients with all cancers (excl. C44) diagnosed between 1998 and 2019. These 112,002 patients with documented progression events during their course of disease represent 34.5 % of the totally 325,026 evaluated cases (incl. M1, n=49,874, 15.3 %). Patients with cancer relapse documented via death certificates only were excluded (n=32,413, 10.0 %). Multiple progression types on different sites are included in the evaluation even when not occurring synchronously. The NOS (not otherwise specified) class is included under the condition, that it is the one and only progression type during the course of disease.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement “not specified” is the only information in registries regarding relapse of the disease. The category “Any type” denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100 % value because patients are potentially considered in more than one subgroup.

Years	Type of progression				
	Any type n=112,002 %	Local relapse n=22,301 %	Lymph node n=7,523 %	Distant metastasis n=77,970 %	NOS n=24,500 %
0	100.0	100.0	100.0	100.0	100.0
1	57.1	65.6	67.9	47.9	72.1
2	41.6	50.1	52.2	30.6	60.8
3	33.6	42.1	43.2	22.0	54.4
4	28.7	36.5	36.5	17.1	49.8
5	25.3	32.8	32.2	14.1	45.9
6	22.8	29.7	28.8	12.1	42.6
7	20.9	27.3	26.3	10.6	40.0
8	19.3	25.4	24.5	9.6	37.6
9	18.1	23.8	23.4	8.8	35.5
10	16.9	22.3	22.0	8.1	33.2

Table 5d. Observed post-progression survival of patients with all cancers (excl. C44) for period 1998-2019 (N=112,002).




Figure 5e. Observed post-progression (any type) survival of 134,588 patients with all cancers (excl. C44) diagnosed between 1988 and 2019 by period of progression.

Years	Period of progression		
	1988-1997 n=16,315 %	1998-2006 n=37,951 %	2007+ n=80,322 %
0	100.0	100.0	100.0
1	54.4	55.2	59.4
2	37.7	39.3	44.4
3	29.0	31.2	36.4
4	23.9	26.5	31.3
5	20.9	23.2	27.7
6	18.5	20.7	25.1
7	16.9	18.8	23.1
8	15.4	17.3	21.4
9	14.2	16.0	20.1
10	12.9	14.9	18.8

Table 5f. Observed post-progression (any type) survival of patients with all cancers (excl. C44) for period 1988-2019 by period of progression (N=134,588).

Shortcuts

MCR	Munich Cancer Registry, Germany	
NCI	National Cancer Institute, USA	
SEER	Surveillance, Epidemiology, and End Results, USA	
UICC	Union for International Cancer Control, Geneva	
DCO	Death certificate only	Death certificate provides the only notification to the registry.
NA	Not available	
NOS	Not otherwise specified	
OS	Overall/Observed survival	Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause
RS	Relative survival	Survival compared to “general population”, ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival
AS	Assembled survival	Assembled chart of observed, expected, relative survival
CS	Conditional survival	Survival probability under the condition of surviving a given period of time
TTP	Time to progression	Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression
1-KM		1 minus Kaplan-Meier estimator (“inverse” Kaplan-Meier estimator)
CI		Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice)
PPS	Post-progression survival	Survival since first progression / relapse (Kaplan-Meier estimate) Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause

Recommended Citation

Munich Cancer Registry. Survival ICD-10 C00-C96.9: All cancers (excl. C44) [Internet]. 2021 [updated 2021 Jan 27; cited 2021 Mar 1]. Available from: <https://www.tumorregister-muenchen.de/en/facts/surv/sC0096E-ICD-10-C00-C96.9-All-cancers-excl.-C44-survival.pdf>

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.